Concord Wealth Partners Ligand Pharmaceuticals Inc Transaction History
Concord Wealth Partners
- $603 Million
- Q4 2024
A detailed history of Concord Wealth Partners transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Concord Wealth Partners holds 12 shares of LGND stock, worth $1,398. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12
Previous 12
-0.0%
Holding current value
$1,398
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding LGND
# of Institutions
259Shares Held
18MCall Options Held
26.8KPut Options Held
9.3K-
Black Rock Inc. New York, NY2.87MShares$335 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.97MShares$230 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.01MShares$118 Million0.05% of portfolio
-
Macquarie Group LTD Australia, C3887KShares$103 Million0.1% of portfolio
-
State Street Corp Boston, MA707KShares$82.4 Million0.0% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $1.97B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...